SCHEMBL4171606

SCHEMBL4171606

Cc1cc(Nc2cnc(C(N)=O)c(Nc3ccc(Cl)cc3)n2)n[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 7/20 0.44
BTK Q06187 2/20 0.44
MEN1 O00255 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
HSD17B10 Q99714 1/20 0.44
RET P07949 2/20 0.43
AURKB Q96GD4 3/20 0.42
IGF1R P08069 3/20 0.41
PAK4 O96013 3/20 0.41
CSNK2A1 P68400 2/20 0.41
PLK4 O00444 2/20 0.41
SRC P12931 2/20 0.41
FGFR1 P11362 2/20 0.41
KDR P35968 2/20 0.41
LRRK2 Q5S007 2/20 0.41
CDC7 O00311 1/20 0.41
CHEK1 O14757 1/20 0.41
PDPK1 O15530 1/20 0.41
DAPK3 O43293 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4178714 0.90 CSNK2A1 (0.45) AURKAMEN1HTTKMT2AHSD17B10
SCHEMBL4173212 0.88 RET (0.44) AURKAMEN1HTTKMT2AHSD17B10
SCHEMBL4171041 0.88 POLB (0.45) AURKAMEN1HTTKMT2AHSD17B10
SCHEMBL4013534 0.88 AURKA (0.43) AURKABTKMEN1HTTKMT2A
SCHEMBL4160448 0.87 RET (0.45) AURKAMEN1HTTKMT2AHSD17B10
SCHEMBL4170177 0.86 RET (0.40) AURKABTKMEN1HTTKMT2A
SCHEMBL4176412 0.85 RET (0.45) AURKAMEN1HTTKMT2AHSD17B10
SCHEMBL4304592 0.84 RET (0.47) AURKAMEN1HTTKMT2AHSD17B10
SCHEMBL4012876 0.83 RET (0.45) AURKAMEN1HTTKMT2AHSD17B10
SCHEMBL4175466 0.83 RET (0.45) AURKAMEN1HTTKMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 US claimed
WO-2009089042-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2009-07-16 WO claimed
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 US disclosed
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 US disclosed
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH MAP3K1, MAP3K15, MAP3K5 AURKA 408/4885BTK 208/4885MEN1 3321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.